Ritlecitinib Therapeutic Cheat Sheet
Alopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre …
Alopecia areata (AA) is a nonscarring alopecia driven by autoreactive cytotoxic CD8 T cells against hair follicle antigens. With an unpredictable clinical course, which can include alopecia totalis and universalis, AA can be debilitating to patients’ quality of life. Historically, glucocorticosteroids, cyclosporine, methotrexate, and azathioprine were used off-label for non-targeted immunosuppre … 
INTRODUCTION
Alopecia areata (AA) is a condition characterized by nonscarring hair loss. Cases of alopecia areata are most commonly seen in patients under age 30 and are frequently idiopathic. In this report, we discuss a woman in her 50s who developed AA shortly after receiving the Tdap vaccine and after one year of guselkumab therapy.
CASE
A woman in her 50s with history of psor … 
Alopecia areata is a CD8+ T-lymphocyte driven autoimmune disorder leading to reversible hair loss. While most commonly presenting as isolated well-demarcated non-cicatricial alopecic patches on the scalp, subtypes of alopecia areata include alopecia totalis with loss of all scalp hair and alopecia universalis with complete loss of all body hair. Although primarily an idiopathic condition, several … 